Anti vascular endothelial growth factor for neovascular age related macular degeneration: a meta analysis of randomized controlled trials
BackgroundTo evaluate the relative efficacy and safety of anti vascular endothelial growth factor (anti VEGF) agents for the treatment of neovascular age related macular degeneration (AMD).MethodsSystematic literature review identifying RCTs comparing anti VEGF agents to another treatment published before June 2016. Efficacy assessed by mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline at up to 2 years followup. Safety assessed by proportions of patients with death, arteriothrombotic and venous thrombotic events, and at least one serious systemic adverse event at up to 2 years of followup.ResultsFifteen RCTs selected for meta analysis (8320 patients) Two trials compared pegaptanib, and three trials compared ranibizumab versus control. Eight trials compared bevacizumab with ranibizumab. Two trials compared aflibercept with ranibizumab. There were no significant differences between bevacizumab and ranibizumab for BCVA at 1 or 2 years (weighted mean difference 0.57, 95% CI 1.55 to 0.41, P 0.25 and weighted mean difference 0.76, 95% CI 2.25 to 0.73, P 0.32, respectively) Ranibizumab was more effective in reducing CMT at 1 year (weighted mean difference 4.49, 95% CI 1.13 to 7.84, P 0.009) Risk ratios comparing rates of serious systemic adverse events at 1 and 2 years were slightly out of favour for bevacizumab. Aflibercept compared with ranibizumab demonstrated similar mean change in BCVA, reduction in CMT, and safety at 1 year.ConclusionsBevacizumab and ranibizumab had equivalent efficacy for BCVA, while ranibizumab had greater reduction in CMT and less rate of serious systemic adverse events. Aflibercept and ranibizumab had comparable efficacy for BCVA and CMT. This provides information to balance comparable effects on vision and risk of adverse events between anti VEGF agents.
BMC Ophthalmology